期刊
CLINICAL GENITOURINARY CANCER
卷 12, 期 6, 页码 408-412出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.clgc.2014.06.012
关键词
Clinical trials; Immune therapy; Relapse risk; Risk reduction; Targeted therapy
In the past few years, several targeted therapies have been approved by the U.S. Food and Drug Administration for the treatment of advanced renal cell carcinoma. This has led to an improvement in the progression-free survival and quality of life for these patients. Nevertheless, the use of these and other therapies in the adjuvant setting has failed to demonstrate a clear benefit. Immune therapies and hormonal or targeted therapies have been studied in this indication, and there are clinical trials currently enrolling patients with high risk of relapse. This article reviews the available data and the ongoing trials exploring the role of adjuvant therapy for kidney cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据